drugset / Trial / NCT02250612

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612

Phase 2 Completed 184 enrolled Sylentis, S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.

Timeline

Start
2014-10
Primary completion
2015-08
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Timolol Other / unclassified 0.5 % Topical
Subject bamosiran Unknown 0.375 % Topical
Subject bamosiran Unknown 0.75 % Topical
Subject bamosiran Unknown 1.125 % Topical
Subject bamosiran Unknown 1.5 % Topical